IMMUNIZATIONTO RITUXIMAB IS MORE FREQUENT IN AUTOIMMUNE SYSTEMIC AUTOIMMUNE DISEASES THAN IN RHEUMATOID ARTHRITIS AND MAY BE MANAGED BY SWITCHING FROM RITUXIMAB TO OFATUMUMAB

被引：0
|
作者：
Combier, Alice [1 ]
Nocturne, Gaetane [1 ]
Henry, Julien [1 ]
Belkhir, Rakiba [1 ]
Pavy, Stephane [1 ]
Mariette, Xavier [1 ]
Seror, Raphaele [1 ]
机构：
[1] Bicetre Hosp, AP HP, Rheumatol, Le Kremlin Bicetre, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3343
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0462
引用
收藏
页码：1695 / 1695
页数：1
相关论文
共 50 条
  • [31] Thyroid hormone autoantibodies in primary Sjögren syndrome and rheumatoid arthritis are more prevalent than in autoimmune thyroid disease, becoming progressively more frequent in these diseases
    R. M. Ruggeri
    M. Galletti
    M. G. Mandolfino
    P. Aragona
    S. Bartolone
    G. Giorgianni
    D. Alesci
    F. Trimarchi
    S. Benvenga
    Journal of Endocrinological Investigation, 2002, 25 : 447 - 454
  • [32] Erratum to Thyroid hormone autoantibodies in primary Sjögren syndrome and rheumatoid arthritis are more prevalent than in autoimmune thyroid disease, becoming progressively more frequent in these diseases
    R.M. Ruggeri
    M. Galletti
    M.G. Mandolfino
    P. Aragona
    S. Bartolone
    G. Giorgianni
    D. Alesci
    F. Trimarchi
    S. Benvenga
    Journal of Endocrinological Investigation, 2002, 25 : V - V
  • [33] Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases
    Niayesh Mohebbi
    Maryam Taghizadeh-Ghehi
    Seyed Mehrdad Savar
    Siamak Abdi
    Romina Kouhsari
    Kheirollah Gholami
    Shahriar Nafissi
    DARU Journal of Pharmaceutical Sciences, 2022, 30 : 323 - 329
  • [34] Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases
    Ramos-Casals, M.
    Garcia-Hernandez, F. J.
    de Ramon, E.
    Callejas, J. L.
    Martinez-Berriotxoa, A.
    Pallares, L.
    Caminal-Montero, L.
    Selva-O'Callaghan, A.
    Oristrell, J.
    Hidalgo, C.
    Perez-Alvarez, R.
    Mico, M. L.
    Medrano, F.
    Gomez-de-la-Torre, R.
    Diaz-Lagares, C.
    Camps, M.
    Ortego, N.
    Sanchez-Roman, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 468 - 476
  • [35] De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases
    Perier, Amandine
    Savey, Lea
    Marcelin, Anne-Genevieve
    Serve, Philippe
    Saadoun, David
    Barete, Stephane
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (11) : 2241 - 2246
  • [36] Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases
    Mohebbi, Niayesh
    Taghizadeh-Ghehi, Maryam
    Savar, Seyed Mehrdad
    Abdi, Siamak
    Kouhsari, Romina
    Gholami, Kheirollah
    Nafissi, Shahriar
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 30 (02) : 323 - 329
  • [37] B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis
    Looney, RJ
    RHEUMATOLOGY, 2005, 44 : II13 - II17
  • [38] Rituximab is an effective treatment for refractory autoimmune bullous diseases but may be associated with considerable side-effects
    Schmidt, E
    Zillikens, D
    Broecker, EB
    Goebeler, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (03) : A14 - A14
  • [39] High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases
    Cervetti, G
    Mechelli, S
    Riccioni, R
    Galimberti, S
    Caracciolo, F
    Petrini, M
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (06) : 877 - 880
  • [40] Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis
    Yoon, Naeun
    Jang, Ah-Kyung
    Seo, Yerim
    Jung, Byung Hwa
    METABOLITES, 2021, 11 (12)
12345